Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment

Article / By

The research highlights the effectiveness of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors as a new standard treatment for advanced or metastatic breast cancer with positive hormone receptors and HER-2 negative. The combination of CDK4/6 inhibitors with endocrine therapy significantly improves progression-free survival, overall survival, and chemotherapy-free intervals compared to hormonal treatments alone. Further investigation into treatment resistance mechanisms is necessary for future advancements.

Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment Read More »

The SONIA trial shows the power and challenges of academic research

Article / By

The SONIA trial demonstrated that patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer can achieve noninferior progression-free survival with deferred second-line treatment using CDK 4/6 inhibitors compared to first-line treatment, while also realizing significant cost savings. However, the authors highlight important limitations of the trial and advocate for CDK 4/6 inhibitors to continue as the standard-of-care first-line therapy due to their impact on overall survival.

The SONIA trial shows the power and challenges of academic research Read More »

Novel combination therapy of osimertinib and Tupichinol E in triple-negative breast cancer: Targeting EGFR and CDK4/6 pathways

Article / By

This study explores the combination therapy of Osimertinib and Tupichinol E in treating Triple-Negative Breast Cancer (TNBC), demonstrating a synergistic effect that reduces cell viability, increases apoptosis, and induces cell cycle arrest. The findings highlight the potential of this novel therapy and the significance of targeting the CDK4/6 pathway in TNBC treatment.

Novel combination therapy of osimertinib and Tupichinol E in triple-negative breast cancer: Targeting EGFR and CDK4/6 pathways Read More »

Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2− Breast Cancer

Article / By

A retrospective analysis of adherence to abemaciclib plus endocrine therapy in women with HR+/HER2− breast cancer found a high adherence rate of 92.25%, with only 12% of patients classified as non-adherent. The study highlights the importance of proactive patient management and thorough communication regarding potential side effects to maintain adherence to treatment.

Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2− Breast Cancer Read More »

Preparation, Optimization, and in-vitro Release Study of Abemaciclib-Loaded Chitosan Nanocarrier as a New Approach for Breast Cancer Treatment

Article / By

The study focuses on enhancing the solubility of Abemaciclib (Abm) by loading it onto a chitosan polymer, resulting in the production of nanoparticles with sizes between 168-192 nm and loading efficiencies of 56.7-62.1%. The in-vitro release study indicates that the Abm-loaded chitosan nanocarrier can extend the release time of Abm to 1400 minutes, suggesting its potential as an alternative drug delivery system for breast cancer treatment.

Preparation, Optimization, and in-vitro Release Study of Abemaciclib-Loaded Chitosan Nanocarrier as a New Approach for Breast Cancer Treatment Read More »

Development and Preclinical Assessment of a Palbociclib Nanostructured Lipid Carrier for Potential Breast Cancer Management

Article / By

The study focuses on developing a palbociclib-loaded nanostructured lipid carrier (PB-NLC) to enhance breast cancer management by improving drug delivery and minimizing side effects. Characterization of the PB-NLC showed favorable properties, including a particle size of 129.8 nm and significantly enhanced bioavailability in vivo, with a 5.9-fold increase compared to palbociclib suspension. The findings suggest that PB-NLC is a promising approach for effective breast cancer treatment.

Development and Preclinical Assessment of a Palbociclib Nanostructured Lipid Carrier for Potential Breast Cancer Management Read More »

A single-centre retrospective evaluation of potential drug-drug interactions in breast cancer patients undergoing CDK 4/6 inhibitors chemotherapy

Article / By

This study evaluates potential drug-drug interactions in breast cancer patients undergoing CDK4/6 inhibitor chemotherapy, revealing that 80.95% of patients experienced such interactions, with a significant portion classified as major or moderate. The findings highlight the importance of assessing these interactions to improve patient care and treatment efficacy.

A single-centre retrospective evaluation of potential drug-drug interactions in breast cancer patients undergoing CDK 4/6 inhibitors chemotherapy Read More »

Effect of Nutritional Teaching Program on Knowledge, Practices, Taste Alterations, and Appetite among Breast Cancer Women undergoing Chemotherapy

Article / By

The study evaluated the effect of a nutritional teaching program on knowledge, practices, taste alterations, and appetite among breast cancer women undergoing chemotherapy. Results showed significant improvements in women’s nutritional knowledge and practical knowledge, as well as slight enhancements in taste alterations and appetite following the program. The findings suggest that regular nutritional education is beneficial for this population.

Effect of Nutritional Teaching Program on Knowledge, Practices, Taste Alterations, and Appetite among Breast Cancer Women undergoing Chemotherapy Read More »

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study

Article / By

The study evaluates the real-world effectiveness and toxicity of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in pretreated patients with metastatic breast cancer. It found that adverse events occurred in over half of the patients treated with either drug, with notable differences in progression-free survival rates among various subgroups. The research offers valuable insights into the clinical use of these agents in a real-world setting.

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study Read More »

Circulating CD3+CD8+ T Lymphocytes as Indicators of Disease Status in Patients With Early Breast Cancer

Article / By

Circulating CD3+CD8+ T lymphocyte levels were found to be lower in breast cancer patients but increased after treatment, then declined upon recurrence. Additionally, elevated levels of plasma CCL2 distinguished breast cancer patients from healthy controls, suggesting that these markers could serve as dual-purpose biomarkers and therapeutic targets in breast cancer management.

Circulating CD3+CD8+ T Lymphocytes as Indicators of Disease Status in Patients With Early Breast Cancer Read More »

Start typing and press enter to search

This site is only for use by healthcare professionals.

By continuing to view this site you are confirming that you are a healthcare professional.

Confirm